NASDAQ:BTMD biote (BTMD) Stock Price, News & Analysis $7.99 +0.12 (+1.52%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.83▼$8.0650-Day Range$5.57▼$8.3652-Week Range$3.65▼$8.44Volume185,783 shsAverage Volume160,927 shsMarket Capitalization$495.70 millionP/E Ratio72.64Dividend YieldN/APrice Target$8.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get biote alerts: Email Address biote MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1.5% Upside$8.11 Price TargetShort InterestBearish5.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 3 Articles This WeekInsider TradingSelling Shares$86,116 Sold Last QuarterProj. Earnings Growth17.86%From $0.56 to $0.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector745th out of 936 stocksMedicinals & Botanicals Industry6th out of 12 stocks 1.5 Analyst's Opinion Consensus Ratingbiote has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coveragebiote has received no research coverage in the past 90 days.Read more about biote's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.29% of the float of biote has been sold short.Short Interest Ratio / Days to Coverbiote has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in biote has recently increased by 38.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbiote does not currently pay a dividend.Dividend Growthbiote does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTMD. Previous Next 2.5 News and Social Media Coverage News Sentimentbiote has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for biote this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BTMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added biote to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, biote insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,116.00 in company stock.Percentage Held by Insiders13.90% of the stock of biote is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of biote is held by institutions.Read more about biote's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for biote are expected to grow by 17.86% in the coming year, from $0.56 to $0.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of biote is 72.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.95.Price to Earnings Ratio vs. SectorThe P/E ratio of biote is 72.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.64.Read more about biote's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About biote Stock (NASDAQ:BTMD)biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Read More BTMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTMD Stock News HeadlinesJuly 11, 2024 | insidertrades.combiote Corp. (NASDAQ:BTMD) CFO Robert Charles Peterson Sells 11,376 Shares of StockJuly 25 at 8:56 PM | finance.yahoo.comBiote Schedules Second Quarter 2024 Financial Results Release and Conference CallJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.June 20, 2024 | businesswire.comBiote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout SharesMay 9, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q1 2024 Earnings Call TranscriptMay 7, 2024 | msn.comBTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | businesswire.comBiote Reports First Quarter 2024 Financial ResultsMay 7, 2024 | seekingalpha.comEsperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlookJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.April 29, 2024 | finance.yahoo.comBiote Announces Definitive Settlement with FounderApril 23, 2024 | businesswire.comBiote Schedules First Quarter 2024 Financial Results Release and Conference CallMarch 25, 2024 | msn.comEsperion stock jumps 18% in wake of FDA label expansionsMarch 18, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed Amid Promising Phase 3 HAE Trial ProspectsMarch 14, 2024 | marketwatch.comBiote Soars 22% With Expected Acceleration in 2H 2024 SalesMarch 13, 2024 | finance.yahoo.combiote Corp. (PNK:BTMD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | finance.yahoo.comBiote Corp (BTMD) Reports Growth Amidst Challenges in Q4 and Full Year 2023March 12, 2024 | businesswire.comBiote Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 11, 2024 | benzinga.comPreview: Biote's EarningsSee More Headlines Receive BTMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BTMD CUSIPN/A CIK1819253 Webbiote.com Phone844-604-1246Fax212-616-9601Employees194Year FoundedN/APrice Target and Rating Average Stock Price Target$8.11 High Stock Price Target$9.00 Low Stock Price Target$6.55 Potential Upside/Downside+1.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio73.00 Forward P/E Ratio14.34 P/E GrowthN/ANet Income$3.32 million Net Margins4.30% Pretax Margin9.26% Return on Equity-36.67% Return on Assets12.50% Debt Debt-to-Equity RatioN/A Current Ratio4.75 Quick Ratio3.97 Sales & Book Value Annual Sales$185.36 million Price / Sales2.69 Cash Flow$0.52 per share Price / Cash Flow15.55 Book Value($0.58) per share Price / Book-13.84Miscellaneous Outstanding Shares62,040,000Free Float53,413,000Market Cap$498.18 million OptionableNot Optionable Beta0.98 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Marc D. Beer (Age 59)Executive Chairman Comp: $470.18kMs. Teresa S. Weber (Age 71)CEO & Director Comp: $1.06MMs. Mary Elizabeth Conlon (Age 43)VP of Business Development, General Counsel & Corporate Secretary Comp: $552.36kMs. Mary J. Puncochar (Age 60)Head of Strategic Sales & Business Analytics Comp: $465.47kMr. Robert C. Peterson (Age 47)Chief Financial Officer Mr. John J. Olsen (Age 67)Chief Information Officer Mr. James Elliott Gibbs IIChief People OfficerMr. Richard Kevin Key (Age 53)Chief Digital Officer Mr. Jade Beutler (Age 61)Head of Nutraceuticals Dr. Cory Rice D.O.Chief Clinical Advisor & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsDecarbonization Plus Acquisition Co. IVNASDAQ:DCRDOPAL FuelsNASDAQ:OPALAdTheorentNASDAQ:ADTHTilrayNASDAQ:TLRYCronos GroupNASDAQ:CRONView All CompetitorsInsiders & InstitutionsSkylands Capital LLCBought 42,729 shares on 7/26/2024Ownership: 0.259%Bank of New York Mellon CorpBought 34,999 shares on 7/26/2024Ownership: 0.152%Bailard Inc.Bought 19,506 shares on 7/26/2024Ownership: 0.031%Allspring Global Investments Holdings LLCBought 5,683 shares on 7/26/2024Ownership: 0.009%Sanders Morris Harris LLCBought 78,259 shares on 7/12/2024Ownership: 0.126%View All Insider TransactionsView All Institutional Transactions BTMD Stock Analysis - Frequently Asked Questions How have BTMD shares performed this year? biote's stock was trading at $4.94 at the beginning of 2024. Since then, BTMD stock has increased by 61.7% and is now trading at $7.99. View the best growth stocks for 2024 here. How were biote's earnings last quarter? biote Corp. (NASDAQ:BTMD) posted its earnings results on Tuesday, May, 7th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.18. The company had revenue of $46.80 million for the quarter, compared to analysts' expectations of $47.09 million. biote had a net margin of 4.30% and a negative trailing twelve-month return on equity of 36.67%. Who are biote's major shareholders? Top institutional shareholders of biote include Skylands Capital LLC (0.26%), Bank of New York Mellon Corp (0.15%), Sanders Morris Harris LLC (0.13%) and Bailard Inc. (0.03%). Insiders that own company stock include Roystone Capital Management Lp, Mary Elizabeth Conlon, Robert Charles Peterson and Samar Jagat Kamdar. View institutional ownership trends. How do I buy shares of biote? Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTMD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
